Selected Favorable Pharmaceutical Intellectual Property Provisions of the USMCA

Published date17 October 2018
Law FirmWilson Sonsini Goodrich & Rosati
AuthorVern Norviel,David Hoffmeister,Louis Lieto
Subject MatterMexico,Patents,Startups,NAFTA,Biologics,Patent Applications,Pharmaceutical Patents,Delays,Canada,Regulatory Reform,Intellectual Property Protection,Pharmaceutical Industry,United States-Mexico-Canada Agreement (USMCA)

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT